Stanford University School of Medicine

HeartBeam Announces Expansion of Its Scientific Advisory Board

Retrieved on: 
Thursday, November 9, 2023
Technology, Medical Devices, Professional Services, Cardiology, Software, Biometrics, Health, Data Analytics, Artificial Intelligence, Medical director, Interventional cardiology, Doctor of Philosophy, Cleveland, AI, International Society, Cleveland Clinic, Baylor Scott & White Medical Center – Temple, Beth Israel Deaconess Medical Center, Physician, American Heart Association, Digital health, Teaching, Electrophysiology, Patient, Ventricular tachycardia, Stanford University, Cardiac catheterization, Atrial fibrillation, Department of Medicine – University of Pamplona, Research, Development, Cornell University, Cordis, United States Air Force Scientific Advisory Board, Digital, Harvard Medical School, Innovation, White, Strategic planning, Stanford University School of Medicine, Arrhythmia, Johnson & Johnson, Weill Cornell Medicine, SAB, Associate, Management, Pharmaceutical industry, Medical device, Medicine, MD, Brigham

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the expansion of its Scientific Advisory Board (SAB) to include several leading cardiologists.

Key Points: 
  • HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the expansion of its Scientific Advisory Board (SAB) to include several leading cardiologists.
  • He is a world-renowned expert in interventional cardiology, and an accomplished inventor, entrepreneur, and investment fund founder.
  • “We are honored and pleased to have such a distinguished group of physicians joining our Scientific Advisory Board,” said Branislav Vajdic, Ph.D., CEO and Founder of HeartBeam.
  • “HeartBeam will benefit tremendously from the input of these leaders in interventional cardiology, electrophysiology, clinical research, and new technologies.

Stanford to use Sequentify kits for Hematological Malignancies NGS Sequencing

Retrieved on: 
Wednesday, November 8, 2023
Regenerative medicine, Acute myeloid leukemia, DNA sequencing, Entrepreneurship, Research, Genomics, NGS, Somatic mutation, Virology, AI, Synthetic biology, National Democratic Front of the Philippines, Automation, AML, Weizmann Institute of Science, DNA, Stanford University School of Medicine, Fine chemical

Founded in 2021, Sequentify democratizes genomics by providing DNA library preparation for Next Generation Sequencing (NGS) and AI software that enables fast, cost-effective and automated sequencing.

Key Points: 
  • Founded in 2021, Sequentify democratizes genomics by providing DNA library preparation for Next Generation Sequencing (NGS) and AI software that enables fast, cost-effective and automated sequencing.
  • Sequentify's NGS products are based on its InfiniSeq proprietary platform and include cancer diagnostics, carrier screening, virology and other applications.
  • Tom Fleischer, Co-Founder and CEO of Sequentify added: "We are excited to work with Stanford Medicine, a world leading research institute and hospital, on implementing cost effective and high throughput NGS sequencing for myeloid conditions."
  • The patent-pending InfiniSeq technology is adjustable to most sequencing machines and fits into any lab workflow.

Fiverr Welcomes Matti Yahav as Chief Marketing Officer and Appoints Yael Garten to its Board of Directors

Retrieved on: 
Thursday, November 2, 2023
Research, Matti, Levi Strauss, Engineering, NYSE, Heart, Stanford University School of Medicine, Data science, SodaStream, Growth, Lego Disney, Marketing, Machine learning, Apple, AI, CMO, Management, Fiverr, Nestlé

The addition of Matti and Yael is part of Fiverr’s broader strategy to build an iconic brand and drive continued innovation.

Key Points: 
  • The addition of Matti and Yael is part of Fiverr’s broader strategy to build an iconic brand and drive continued innovation.
  • Matti brings with him over 20 years of marketing experience to Fiverr.
  • He has worked with some of the world’s most recognizable brands, including Lego, Disney, Nestle, and SodaStream.
  • During his time at SodaStream, Matti spent over seven years on the Global Management Team, five of which were as CMO.

Lupus Foundation of America Awards Grants to Two Early Career Scientists, Funding Studies in Pregnancy and Personalized Medicine

Retrieved on: 
Tuesday, October 31, 2023
Lupus Foundation of America, MPH, Heart, Stanford University School of Medicine, Research, Mentorship, Lupus, Disease, Gary, CDA, Pregnancy, Advisory Council, Gene, Woman, Immunology, Patient, Nursing, Pharmaceutical industry, MD

WASHINGTON, Oct. 31, 2023 /PRNewswire-PRWeb/ -- The Lupus Foundation of America is pleased to announce the grantees of the 2023 Gary S. Gilkeson Career Development Award (CDA) .

Key Points: 
  • WASHINGTON, Oct. 31, 2023 /PRNewswire-PRWeb/ -- The Lupus Foundation of America is pleased to announce the grantees of the 2023 Gary S. Gilkeson Career Development Award (CDA) .
  • The two-year grant supports early career scientists and their crucial lupus research alongside experienced mentors who will guide them and help continue to build their future in the lupus research field.
  • "The Lupus Foundation of America's Gary S. Gilkeson Career Development Award not only provides funding that is often difficult to obtain for early career scientists, but the mentorship that is so important in establishing a strong career in lupus research.
  • Learn more about the Gary S. Gilkeson Career Development Award and its 2023 grantees, here .

Kyiv to Host International Healthcare Summit on War Zone Medicine

Retrieved on: 
Tuesday, October 31, 2023
Public health, Clinical professor, Surgeon General of the United States, California Pacific Medical Center, Organization, Summit, Amputation, University of Maryland School of Public Health, Learning, Non-governmental organization, Surgeon, International healthcare accreditation, Hospital, Stanford University School of Medicine, Maryland School, University, Pain management, University of Pennsylvania Health System, Mayo Clinic, Rear admiral, Saint Louis University School of Medicine, Dentistry, Pharmaceutical industry

COLUMBUS, Ohio, Oct. 31, 2023 /PRNewswire/ -- (JANZ Corporation) -- As war rages in Ukraine and Gaza, a former U.S. Surgeon General will be among the medical professionals gathering in Kyiv next week to discuss the challenges of providing medical care in active war zones.

Key Points: 
  • Surgeon General will be among the medical professionals gathering in Kyiv next week to discuss the challenges of providing medical care in active war zones.
  • To learn more and/or register to attend physically or virtually for the International Healthcare Summit-Ukraine 2023, please visit www.internationalhealthcaresummit.org .
  • "The situation in Ukraine is absolutely catastrophic," said Dr. Andrii Strokan, chief clinical medical officer at Feofaniya Hospital in Kyiv, Ukraine.
  • Strokan, who led the team of surgeons visiting the Mayo Clinic, will be joined in Kyiv at the healthcare summit by former Surgeon General of the United States (Acting), Rear Admiral
    (ret.)

Complete Genomics demonstrates technical and commercial momentum in the sequencing market through new customers, partnerships and collaborations less than one year after launching in the U.S.

Retrieved on: 
Tuesday, October 31, 2023
Complete Genomics, ASHG, RNA-Seq, Nebula Genomics, Karkus, G400, Whole genome sequencing, IDT, Medical laboratory, Bio-Rad Laboratories, RNA, University of Massachusetts, Face, Professor, Research, SNP, Society, American Society of Human Genetics, Ecosystem, Partnership, WGS, Human genetics, Google AI, Sequoia, Integrated DNA Technologies, Automation, New England Biolabs, Integration, New England, Completeness, Stanford University School of Medicine, Antibiotics, Medical device, Genomics

At ASHG, Complete Genomics will highlight experts from Stanford Medicine, UMass Chan Medical School and Praxis Genomics to discuss how affordable and accurate genomic sequencing is changing the face of research.

Key Points: 
  • At ASHG, Complete Genomics will highlight experts from Stanford Medicine, UMass Chan Medical School and Praxis Genomics to discuss how affordable and accurate genomic sequencing is changing the face of research.
  • See the full description of speakers Complete Genomics is bringing to ASHG at completegenomics.com/ashg-2023-event-page .
  • Based in San Jose, CA, Complete Genomics celebrated its U.S. commercial launch of its DNBSEQ™ sequencing product line one year ago at ASHG 2022.
  • "Our collaboration with Complete Genomics underscores our commitment to providing researchers with advanced solutions for sequencing applications."

BioMendics to Present on Epidermolysis Bullosa Simplex at the 7th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases

Retrieved on: 
Monday, October 30, 2023
Drug development, EBS, Chronic pain, Itch, Blister, Doctor of Philosophy, Autophagy, Epidermolysis bullosa simplex, Cell, Skin, Phase, Skin condition, Patient, Stanford University School of Medicine, Pharmaceutical industry, Dermatology

ROOTSTOWN, Ohio, Oct. 30, 2023 /PRNewswire/ -- BioMendics LLC, a pharmaceutical company developing new medicines to improve the lives of patients living with rare skin diseases, today announced its participation in the 7th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases, taking place from October 31 - November 2 in Boston, Massachusetts.

Key Points: 
  • ROOTSTOWN, Ohio, Oct. 30, 2023 /PRNewswire/ -- BioMendics LLC, a pharmaceutical company developing new medicines to improve the lives of patients living with rare skin diseases, today announced its participation in the 7th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases, taking place from October 31 - November 2 in Boston, Massachusetts.
  • Dr. Karen McGuire, CEO and Founder of BioMendics, will provide an update on the company's primary clinical program in epidermolysis bullosa simplex (EBS).
  • BioMendics completed their TAMES Phase I/IIa study with Stanford Medicine, Dermatology this summer in patients with severe EBS, and is planning on a Phase II study in 2024.
  • The completion of the Phase I/IIa study came on the heels of BioMendics receiving Orphan Drug Designation on May 1, 2023, for their proprietary molecule, BM-3103.

GSR Ventures Survey: Generative AI Shaking Up Digital Health Investors' Funding Strategies and Industry Outlooks

Retrieved on: 
Thursday, October 26, 2023
Digital, MD, AI, PALO, Automation, MBA, Ophthalmology, Stanford University School of Medicine, Nursing, Cryptocurrency

PALO ALTO, Calif., Oct. 26, 2023 /PRNewswire/ -- Digital health investors say generative AI, oncology care and the challenges posed by clinician shortages are transforming their startup funding strategies and investment outlooks for the healthcare industry, according to the results of an online survey from GSR Ventures. Startup company valuation expectations among backers, however, are significantly lower than in 2022.

Key Points: 
  • "Digital health investors are a small, but highly influential community driving the innovations that will transform how care is delivered and managed, and blockbuster new therapies that are discovered," said Sunny Kumar, MD, a partner at GSR Ventures.
  • Nearly 9 out of 10 (87%) said generative AI solutions have influenced their investment strategies.
  • "It will be exciting to witness over the remainder of 2023 into 2024 the many new generative AI healthcare startups that enter the market.
  • Hopefully, investor enthusiasm drives greater adoption of such technologies across an industry that would massively benefit from greater automation and efficiency."

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting

Retrieved on: 
Sunday, October 22, 2023
Gastroenterology, FDA, Comorbidity, Hepatorenal syndrome, American College, Respiratory failure, PDT, EDT, Heart rate, Boxed warning, Oxygen saturation (medicine), Use, DBP, Physician, ACG, Cirrhosis, Mortality, Effect, Treatment, Post hoc analysis, MAP, SBP, Acute kidney injury, American College of Gastroenterology, Research, ACLF, Baylor University Medical Center, Phase, White, Chronic liver disease, Risk, Hospital, Maryland School, Volume overload, University, Stanford University School of Medicine, CLD, Blood pressure, HRS, Hypoxia, Pharmaceutical industry, Dietary supplement, Medical device, Nursing, Communications satellite, Mallinckrodt, Patient, MD, Terlipressin

DUBLIN, Oct. 22, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced that three posters detailing findings from Mallinckrodt's latest clinical and health economics outcomes research with TERLIVAZ® (terlipressin) for injection for adult patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function1,2,3,4 will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Vancouver, British Columbia, taking place October 20-25, 2023.

Key Points: 
  • Outcomes may be influenced by therapies not evaluated in the study and the clinical/health economic outcomes may not be solely attributable to TERLIVAZ.
  • TERLIVAZ® is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.
  • For patients with high prioritization for liver transplantation (e.g., MELD ≥35), the benefits of TERLIVAZ may not outweigh its risks.
  • If TERLIVAZ is used during pregnancy, the patient should be informed of the potential risk to the fetus.

Englewood Health Appoints Two New Physician Leaders to Roles in Behavioral Health and Health Equity

Retrieved on: 
Thursday, October 19, 2023
American Diabetes Association, Psychiatry, University, Education, Endocrine Society, Health, American Psychiatric Association, Stanford University School of Medicine, MD, Maimonides Medical Center, Endocrinology, Diabetes, Metabolism, Saint Andrew's Society, Traumatic brain injury, Northwell Health, Health equity, Student, Internal medicine, Long Island, Cancer, Addiction medicine, Patient, Diagnosis, Mental health, Hospital, Pharmaceutical industry, Nursing, Medical device, Pharmacy

ENGLEWOOD, N.J., Oct. 19, 2023 /PRNewswire/ -- Englewood Health has appointed two new physician leaders to oversee behavioral health and health equity.

Key Points: 
  • ENGLEWOOD, N.J., Oct. 19, 2023 /PRNewswire/ -- Englewood Health has appointed two new physician leaders to oversee behavioral health and health equity.
  • "We are delighted to welcome Dr. Spariosu as director of behavioral health," says Hillary Cohen, MD, senior vice president for medical affairs at Englewood Health.
  • Under her leadership, Englewood Health will build on its success and further meet the behavioral health needs of our communities."
  • Under her guidance, Englewood Health will implement targeted interventions designed to improve health outcomes and health equity for our communities."